187 related articles for article (PubMed ID: 37426624)
1. Immune checkpoint inhibitors in cancer patients with COVID-19.
Pan Y; Tan J; Li J; Li T; Li J; Cao Y; Yang L; Lin X; Li M; Liang X
Open Life Sci; 2023; 18(1):20220641. PubMed ID: 37426624
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibition in COVID-19: risks and benefits.
Pezeshki PS; Rezaei N
Expert Opin Biol Ther; 2021 Sep; 21(9):1173-1179. PubMed ID: 33543652
[TBL] [Abstract][Full Text] [Related]
3. Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection.
Gambichler T; Reuther J; Scheel CH; Susok L; Kern P; Becker JC
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207589
[TBL] [Abstract][Full Text] [Related]
4. Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
Yuen KCJ; Mortensen MJ; Azadi A; Fonkem E; Findling JW
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00246. PubMed ID: 34268454
[TBL] [Abstract][Full Text] [Related]
5. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
Aeppli S; Eboulet EI; Eisen T; Escudier B; Fischer S; Larkin J; Gruenwald V; McDermott D; Oldenburg J; Omlin A; Porta C; Rini B; Schmidinger M; Sternberg C; Rothermundt C
ESMO Open; 2020 Jul; 5(Suppl 3):. PubMed ID: 32669298
[TBL] [Abstract][Full Text] [Related]
6. Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak.
Tagliamento M; Spagnolo F; Poggio F; Soldato D; Conte B; Ruelle T; Barisione E; De Maria A; Del Mastro L; Di Maio M; Lambertini M
Eur J Clin Invest; 2020 Sep; 50(9):e13315. PubMed ID: 32535890
[TBL] [Abstract][Full Text] [Related]
7. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade.
Niewolik J; Mikuteit M; Cossmann A; Vahldiek K; Gutzmer R; Müller F; Schröder D; Heinemann S; Behrens GMN; Dopfer-Jablonka A; Steffens S; Grimmelmann I
Oncology; 2022; 100(7):392-398. PubMed ID: 35609553
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
Hijmering-Kappelle LBM; Hiltermann TJN; Bensch F
Clin Lung Cancer; 2022 Mar; 23(2):143-150. PubMed ID: 35034861
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
Dipasquale A; Persico P; Lorenzi E; Rahal D; Santoro A; Simonelli M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33574054
[TBL] [Abstract][Full Text] [Related]
15. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
Ghosh N; Tirpack A; Chan KK; Bass AR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
[TBL] [Abstract][Full Text] [Related]
17. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis.
Qian W; Ye Y; Zuo L; Song T; Xu Q; Wang Y; Qian J; Tian Y
Immunotherapy; 2021 Oct; 13(15):1271-1282. PubMed ID: 34431319
[TBL] [Abstract][Full Text] [Related]
19. Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.
Tan R; Yun C; Seetasith A; Sheinson D; Walls R; Ngwa I; Reddy JC; Zhang Q; Secrest MH; Lambert P; Sarsour K
Oncologist; 2022 Mar; 27(3):236-243. PubMed ID: 35274714
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis.
Dumoulin DW; Gietema HA; Paats MS; Hendriks LEL; Cornelissen R
Front Oncol; 2020; 10():577696. PubMed ID: 33194697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
